title: Evidence-based recommendations for the use of WBC-reduced cellular blood components.
authors.affiliation: Technology Assessment Group, Clinical Practice Advancement Center, University Health System Consortium, Oak Brook, Illinois 60523-1890, USA. ratko@uhc.edu
authors.forename: T A
authors.initials: TA
authors.lastname: Ratko
authors.forename: J P
authors.initials: JP
authors.lastname: Cummings
authors.forename: H A
authors.initials: HA
authors.lastname: Oberman
authors.forename: K P
authors.initials: KP
authors.lastname: Crookston
authors.forename: P J
authors.initials: PJ
authors.lastname: DeChristopher
authors.forename: D T
authors.initials: DT
authors.lastname: Eastlund
authors.forename: J E
authors.initials: JE
authors.lastname: Godwin
authors.forename: R A
authors.initials: RA
authors.lastname: Sacher
authors.forename: D H
authors.initials: DH
authors.lastname: Yawn
authors.forename: K A
authors.initials: KA
authors.lastname: Matuszewski
mesh_terms: D016913:Blood Component Transfusion / Q000009:adverse effects / Q000379:methods / Q000592:standards*; D001793:Blood Preservation; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D006801:Humans; D007937:Leukapheresis / Q000191:economics / Q000379:methods / Q000592:standards; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence; D016635:Universal Precautions